TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts TCRX Hot Sheet
Join SI Premium – FREE
TScan Therapeutics, Inc. (NASDAQ: TCRX) reported Q3 EPS of ($0.25), $0.06 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $1.04 million versus the consensus estimate of $1.17 million.
For earnings history and earnings-related data on TScan Therapeutics, Inc. (TCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
- Celcuity (CELC) Misses Q2 EPS by 28c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
